Video
Dr. Brose on Lenvatinib in Differentiated Thyroid Cancer
Author(s):
Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses survival benefit and possible combination strategies with the lenvatinib in patients with radioactive iodine refractory differentiated thyroid cancer.
Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses survival benefit and possible combination strategies with the lenvatinib in patients with radioactive iodine refractory differentiated thyroid cancer.
Brose and her team looked at lenvatinib, which was FDA approved for this patient population in February 2015, in patients over 65 in a preplanned analysis of the phase III SELECT trial.
In this analysis, researchers found that patients over 65 who received lenvatinib had a median progression-free survival of 16.7 months versus 3.7 months with placebo. The hazard ratio was .53.
Brose also discusses possible future combinations with lenvatinib for thyroid cancer in all age groups, including possible pairings with everolimus and pembrolizumab.
<<<
